Innovotech Announces Grant of Stock Options

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

(TheNewswire)



Edmonton – TheNewswire - October 20,  2020. Innovotech Inc. (“Innovotech”) (TSXV:IOT)  wishes to announce that, in accordance with the policies of the TSX Venture Exchange, the board of directors has approved a grant of stock options to directors and officers of Innovotech to purchase an aggregate of 295,000 common shares pursuant to its stock option plan.  These options have an exercise price of $0.21 per common share and expire on October 13, 2025.

  

About Innovotech Inc.

Innovotech is a Canadian biotechnology company owning proprietary intellectual property, conducting

contract research, and owning and providing proprietary devices for testing in multiple applications in

microbiology.

 

Alan Savage

Director & CFO

Innovotech Inc.

604-220-4935

[email protected]

 

This document may contain forward-looking statements that are predictive in nature and subject to risks and

uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past

results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to

such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of

predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small

number of customers including government organizations; fluctuations in operating results; government policies or

actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual

property protection and potential costs associated with its defense; the Company’s exposure to lawsuits and other

matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should

management’s assumptions prove inaccurate, actual results could vary materially from those anticipated. The

Company undertakes no obligation to publicly make or update any forward-looking statements, except as required

by applicable law.

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy of accuracy of this release.

 

Copyright (c) 2020 TheNewswire - All rights reserved.